Optimal brand coverage and performance across managed markets
Treatment value and patient outcomes with innovative AI-enabled solutions.
Managed care analytics
Outcomes-oriented policy changes and pricing pressures from overlapping market fragments introduce countless changes in the life sciences managed care ecosystem. These industry forces continuously transform the payer and provider landscape. Managed markets teams are seeking data-driven analytics capabilities to address such market access challenges and requirements.
Deep experience across traditional and emerging market access data sources can feed AI-driven solutions to answer pressing business questions. Axtria’s managed care analytics techniques harness the power of cross-channel data sets to provide ‘where to play’ and ‘how to win’ strategies in a multi-stakeholder model, driving product performance and coverage.
AI/ML-driven solution applications
Predict brand share impact with market access and contracting changes for informed strategies and rebate discussions
Measure the impact of payers on brand performance with multivariate modeling for direct and indirect quantification
Analyze market access scenarios to enable granular plan-level contracting decisions
Axtria’s comprehensive ‘managed care framework’ and performance indicators
Customer groups
- Payer access
- Sales performance
- Rebates
- Claims rejections and reversals
- Sales performance
- Channel distribution (Hospital/IDN/GPO)
- Chargebacks
- Copay cards
- Vouchers
- Rebate programs
- Benefit investigations
- Wholesale and downstream inventory
- Trade SLA compliance
Axtria research hub
Report
From Chaos to Cohesion: The Power of Productized Marketing
Webinar
Keeping Omnichannel Marketing Analytics Simple
White Paper
Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs: What Does This Mean For Pharma Companies?
Customer success stories
Case Study
8% Jump in Revenue With an Axtria MarketingIQ - based Global Marketing Mix Solution
Case Study
Marketing Mix Analysis For A Specialty GI Drug Contributed Significant Top-Line Growth For A Top-10 Pharma Company
Case Study